Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
Indexed incrossrefpubmed
Abstract
Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor–modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had previously received ibrutinib. Methods Twenty-four patients with CLL received lymphodepleting chemotherapy and anti-CD19 CAR-T cells at one of three dose levels (2 × 10 5 , 2 × 10 6 , or 2 × 10 7 CAR-T cells/kg). Nineteen patients experienced disease progression while receiving ibrutinib, three were ibrutinib intolerant, and two did not experience progression while receiving ibrutinib. Six patients were venetoclax refractory, and 23 had a complex karyotype and/or 17p deletion. Results Four weeks after CAR-T cell infusion, the overall…
Citation impact
656
total citations
- FWCI
- 35.54
- Percentile
- 100%
- References
- 26
Citations per year
Authors
12Topics & keywords
Topics
Keywords
- Ibrutinib
- Medicine
- Fludarabine
- Chronic lymphocytic leukemia
- Cyclophosphamide
- Chimeric antigen receptor
- Leukemia
- Internal medicine
No related works found for this paper.